TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer

By sjmartinez • June 30, 2023

Bardia A, Jhaveri K, Kalinsky K, Pernas S, Tsurutani J, Xu B, Hamilton E, Im SA, Nowecki Z, Sohn J, Laurentiis M, Jañez NM, Adamo B, Lee KS, Jung KH, Rubovszky G, Tseng LM, Lu YS, Yuan Y, Maxwell MJ, Haddad V, Khan SS, Rugo HS, Pistilli B. TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer. Future Oncol. 2023 Jun 30. doi: 10.2217/fon-2023-0188. Epub ahead of print. PMID: 37387213.

Tags: antibody-drug conjugate (ADC), Cedars Sinai DoM, datopotamab deruxtecan (Dato-DXd), Hematology/Oncology, HR-positive/HER2-negative, inoperable breast cancer, metastatic breast cancer, Publications, Trophoblast cell surface antigen 2 (TROP2)

Artificial intelligence applied to coronary artery calcium scans (AI-CAC) significantly improves cardiovascular events prediction

Naghavi M, Reeves AP, Atlas K, Zhang C, Atlas T, Henschke CI, Yankelevitz DF, Budoff MJ, Li D, Roy SK, Nasir K, Molloi S, Fayad[...]

Machine learning-based clustering identifies obesity subgroups with differential multi-omics profiles and metabolic patterns

Anwar MY, Highland H, Buchanan VL, Graff M, Young K, Taylor KD, Tracy RP, Durda P, Liu Y, Johnson CW, Aguet F, Ardlie KG, Gerszten[...]

Clinical Correlates of a Single-item Physical Activity Questionnaire among Patients Undergoing Stress SPECT Myocardial Perfusion Imaging

Rozanski A, Gransar H, Miller RJ, Han D, Hayes S, Friedman J, Thomson L, Berman D. Clinical Correlates of a Single-item Physical Activity Questionnaire among[...]